Urovant Sciences Ltd Net debt/EBITDA
Was ist das Net debt/EBITDA von Urovant Sciences Ltd?
Net debt/EBITDA von Urovant Sciences Ltd ist -1.53
Was ist die Definition von Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Urovant Sciences Ltd
Unternehmen mit net debt/ebitda ähnlich Urovant Sciences Ltd
- Invo Bioscience Inc hat Net debt/EBITDA von -1.55
- HCL Technologies hat Net debt/EBITDA von -1.54
- Hurricane Plc hat Net debt/EBITDA von -1.54
- Materialise Nv hat Net debt/EBITDA von -1.53
- Great Wall Motor hat Net debt/EBITDA von -1.53
- Jaguar Mining hat Net debt/EBITDA von -1.53
- Urovant Sciences Ltd hat Net debt/EBITDA von -1.53
- Ctac NV hat Net debt/EBITDA von -1.53
- King Global Ventures hat Net debt/EBITDA von -1.53
- Sirius International Insurance hat Net debt/EBITDA von -1.53
- Vital Mobile hat Net debt/EBITDA von -1.52
- Vintage hat Net debt/EBITDA von -1.52
- Genworth Inc hat Net debt/EBITDA von -1.52